Literature DB >> 33216305

Peripherally restricted cannabinoid type 1 receptor (CB1R) antagonist, AM6545, potentiates stress-induced hypothalamic-pituitary-adrenal axis activation via a non-CB1R mechanism.

Christopher J Roberts1,2,3, Cecilia J Hillard4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33216305      PMCID： PMC8528513          DOI： 10.1007/s12020-020-02549-1

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  20 in total

1.  A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents.

Authors:  N L Cluny; V K Vemuri; A P Chambers; C L Limebeer; H Bedard; J T Wood; B Lutz; A Zimmer; L A Parker; A Makriyannis; K A Sharkey
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  Endocannabinoid signaling mediates cocaine-induced inhibitory synaptic plasticity in midbrain dopamine neurons.

Authors:  Bin Pan; Cecilia J Hillard; Qing-song Liu
Journal:  J Neurosci       Date:  2008-02-06       Impact factor: 6.167

3.  Peripheral endocannabinoid signaling controls hyperphagia in western diet-induced obesity.

Authors:  Donovan A Argueta; Nicholas V DiPatrizio
Journal:  Physiol Behav       Date:  2017-01-05

4.  Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function.

Authors:  Daniela Cota; Michel-Alexander Steiner; Giovanni Marsicano; Cristina Cervino; James P Herman; Yvonne Grübler; Johanna Stalla; Renato Pasquali; Beat Lutz; Günter K Stalla; Uberto Pagotto
Journal:  Endocrinology       Date:  2006-12-28       Impact factor: 4.736

5.  Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.

Authors:  Torbjörn U C Järbe; Brian J LeMay; V Kiran Vemuri; Subramanian K Vadivel; Alexander Zvonok; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2011-03-03       Impact factor: 4.530

6.  A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome.

Authors:  Nicole P Bowles; Ilia N Karatsoreos; Xiaosong Li; V Kiran Vemuri; Jodi-Anne Wood; Zhiying Li; Kellie L K Tamashiro; Gary J Schwartz; Alexandros M Makriyannis; George Kunos; Cecilia J Hillard; Bruce S McEwen; Matthew N Hill
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-22       Impact factor: 11.205

7.  Immunocytochemical demonstration of CB1 cannabinoid receptors in the anterior lobe of the pituitary gland.

Authors:  T Wenger; J J Fernández-Ruiz; J A Ramos
Journal:  J Neuroendocrinol       Date:  1999-11       Impact factor: 3.627

8.  Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.

Authors:  Sherrica Tai; Spyros P Nikas; Vidyanand G Shukla; Kiran Vemuri; Alexandros Makriyannis; Torbjörn U C Järbe
Journal:  Psychopharmacology (Berl)       Date:  2015-03-15       Impact factor: 4.530

9.  The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior.

Authors:  P A Randall; V K Vemuri; K N Segovia; E Ferreris Torres; S Hosmer; E J Nunes; J L Santerre; A Makriyannis; J D Salamone
Journal:  Pharmacol Biochem Behav       Date:  2010-08-14       Impact factor: 3.533

10.  Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS.

Authors:  Mohab M Ibrahim; Hongfeng Deng; Alexander Zvonok; Debra A Cockayne; Joyce Kwan; Heriberto P Mata; Todd W Vanderah; Josephine Lai; Frank Porreca; Alexandros Makriyannis; T Philip Malan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-13       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.